Compatible Materials Individual infusion sites of care should follow best medical practices when determining materials to use. Procurement of materials from a specific vendor or vendors is not required. If alternate materials are used, the compatibility of these materials should be confirmed with that vendor. Bamalanivimab has no known incompatibilities with conventional medical supplies and equipment. During clinical trials, Lilly has used the following materials: • Polypropylene syringes • Stainless steel needles • Polyvinylchloride (PVC) IV bags with or without DEHP • Polyvinylchloride (PVC) infusion sets with or without DEHP containing an in-line polyethersulfone (PES)* filter (Please see footnote.) Storage Refrigerate unopened vials at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze, shake or expose to direct light. Preparation and Administration • The 700 mg dose MUST BE prepared using 0.9% sodium chloride. • Preparation of 700 mg dose of bamlanivimab for IV infusion* • Administration of a dose of 700 mg of bamlanivimab in an IV infusion* *Applicable state/local/federal agencies, regulatory bodies, and industry standards (e.g. USP 797, NICA Standards for In-Office Infusion). • Bamlanivimab solution for infusion should be prepared by a qualified health care professional using aseptic technique. • Refer to section on Preparation Summary Table for 700mg Dose of Bamlanivimab Solution for Intravenous Infusion for additional dose preparation information. • Remove ONE (1) vial of bamlanivimab injection, 700mg/20mL (drug product) from refrigerated storange at 2°C to 8°C (36°F to 46°F), and equilibrate the vial to room temperature, not exceeding 30°C or 86°F for approximately 20 minutes (or no longer cool to the touch). Do not expose to direct heat. • Gently invert the vial by hand approximately 10 times to ensure homogeneity of the contents. Do not shake or vigorously agitate the vial. Visually inspect the vial for the presence of any visible particulate matter and discoloration. Bamlanivimab is a clear to slightly opalescent and colorless to slightly yellow to slightly brown solution. If visible particulate matter is observed, appropriately discard the vial, obtain a new vial, and restart the preparation, beginning at the prior step. • Prepare the IV solution using the following approach using aseptic technique. • The IV solution can be prepared using a filled 250mL IV bag. Using a syringe with an 18-gauge needle, withdraw a total of 70mL of 0.9% sodium chloride from the IV bag and discard that volume, leaving 180mL in the IV bag. • Using a new, sterile syringe with an 18-gauge needle, withdraw 20mL of bamlanivimab from the prepared vial and inject the contents into the prepared IV bag, so that the combined total volume is 200mL. • Gently invert the prepared IV bag by hand approximately 10 times to ensure homogeneity of the contents. Do not shake or vigorously agitate the prepared bag. Avoid foaming. Visually inspect the bag after preparation. The contents of the bag should be free of any visible particulate matter. Obtain new vial(s) and re-prepare the dose if visible particulate matter is observed. *If alternate materials are used, the compatibility of these materials should be confirmed with that vendor. Bamalanivimab has no known incompatibilities with conventional medical supplies and equipment. Lilly Bamlanivimab Antibody Playbook | 17 PP-BM-US-0024